MCID: HPT046
MIFTS: 59

Hepatic Veno-Occlusive Disease

Categories: Cardiovascular diseases, Endocrine diseases, Gastrointestinal diseases, Liver diseases, Rare diseases

Aliases & Classifications for Hepatic Veno-Occlusive Disease

MalaCards integrated aliases for Hepatic Veno-Occlusive Disease:

Name: Hepatic Veno-Occlusive Disease 12 77 54 60 56 45 15 74
Sinusoidal Obstruction Syndrome 54 60
Veno-Occlusive Disease 12 56
Hepatic Venoocclusive Disease 77
Hepatic Vein Thrombosis 74
Hepatic Vein Occlusion 74
Venoocclusive Disease 74
Budd-Chiari Syndrome 74

Characteristics:

Orphanet epidemiological data:

60
hepatic veno-occlusive disease
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 60  
Rare hepatic diseases


External Ids:

Disease Ontology 12 DOID:0080177
MeSH 45 D006504
ICD10 34 K76.5
MESH via Orphanet 46 D006504
ICD10 via Orphanet 35 K76.5
UMLS via Orphanet 75 C0019156
Orphanet 60 ORPHA890

Summaries for Hepatic Veno-Occlusive Disease

NIH Rare Diseases : 54 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs.Orpha Number: 890Disease definitionHepatic veno-occlusive disease (hepatic VOD) is a condition resulting from toxic injury to the hepatic sinusoidal capillaries that leads to obstruction of the small hepatic veins.EpidemiologyPrevalence is unknown but hepatic VOD is a rare disease. Endemic zones have been identified in which the disease is associated with the consumption of herbal tea containing pyrrolizidine alkaloids. Epidemics affecting several hundred individuals may occur after contamination of the harvest with these plants.Clinical descriptionIt affects children and adults. The clinical picture is characterized by painful hepatomegaly, jaundice, and fluid retention that manifests by weight gain, edemas, and ascites. Hepatic insufficiency manifesting as coagulopathy and hepatic encephalopathy may occur. Functional renal insufficiency is common. In severe cases, multiple organ failure or severe bacterial infections may occur.In developed countries, hepatic veno-occlusive disease is mainly associated with the conditioning regimen for hematopoietic stem cell transplantation, with 10 to 60% of transplant patients (depending on the conditioning regimen protocol used) developing hepatic VOD. Hepatic VOD may also occur after chemotherapy or radiation therapy.EtiologyHepatic sinusoidal endothelial cell lesions appear to be the primary cause of the disease, leading to non-thrombotic occlusion of hepatic veins with concentric subendothelial thickening associated with edema and eventually fibrosis.Diagnostic methodsDiagnosis is based on recognition of the clinical manifestations (hepatomegaly, jaundice, and weight gain) and their association with a potential cause of hepatic VOD (hematopoietic stem cell transplantation or chemotherapy, exposure to pyrrolizidine alkaloids), together with exclusion of other causes of liver disease. Liver biopsy is often indicated. Imaging studies, particularly hepatic Doppler-ultrasonography, may help to confirm the diagnosis.Differential diagnosisDifferential diagnoses include other causes of acute or chronic liver disease, and, in the case of hematopoietic stem cell transplantation, graft-versus-host disease and severe infections.Management and treatmentNo specific treatment is available. Defibrotide is frequently used, mainly on the basis of limited studies (historic comparisons) and because side effects are uncommon. Preventive treatment with heparin is often indicated, but its efficacy has not been proven. In case of hematopoietic stem cell transplantation, the main prophylactic treatment is the use of less hepatotoxic conditioning regimens.PrognosisSeverity and course of the disease vary between patients. In severe cases, the prognosis is poor with a high mortality rate (up to 90%) due to multiple organ failure.Visit the Orphanet disease page for more resources.

MalaCards based summary : Hepatic Veno-Occlusive Disease, also known as sinusoidal obstruction syndrome, is related to pulmonary hypertension and portal vein thrombosis. An important gene associated with Hepatic Veno-Occlusive Disease is SERPINC1 (Serpin Family C Member 1), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Collagen chain trimerization. The drugs Busulfan and Ledipasvir have been mentioned in the context of this disorder. Affiliated tissues include liver, bone and bone marrow, and related phenotypes are hepatomegaly and renal insufficiency

Disease Ontology : 12 A hepatic vascular disease that is characterized by obstruction of some of the small veins of the liver.

Wikipedia : 77 Hepatic veno-occlusive disease or veno-occlusive disease with immunodeficiency (VODI) is a condition in... more...

Related Diseases for Hepatic Veno-Occlusive Disease

Diseases related to Hepatic Veno-Occlusive Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 257)
# Related Disease Score Top Affiliating Genes
1 pulmonary hypertension 31.0 F3 PLAT THBD
2 portal vein thrombosis 30.5 SERPINC1 SERPINE1
3 ischemic colitis 30.5 SERPINC1 SERPINE1
4 purpura 29.8 F3 SERPINC1 THBD THPO
5 bone marrow cancer 29.7 FGF2 THBD THPO
6 thrombosis 29.0 F3 F8 PLAT SERPINC1 SERPINE1 THBD
7 hepatic venoocclusive disease with immunodeficiency 12.6
8 pulmonary venoocclusive disease 12.6
9 pulmonary venoocclusive disease 1, autosomal dominant 12.4
10 hematopoietic stem cell transplantation 10.8
11 leukemia 10.4
12 pulmonary hypertension, primary, 1 10.4
13 lymphoma 10.4
14 platelet aggregation, spontaneous 10.4 PLAT SERPINC1
15 plasminogen activator inhibitor-1 deficiency 10.4 PLAT SERPINE1
16 central serous chorioretinopathy 10.4 PLAT SERPINE1
17 posterior myocardial infarction 10.4 PLAT SERPINC1
18 mercury poisoning 10.4 PLAT THBD
19 encephalopathy, familial, with neuroserpin inclusion bodies 10.4 PLAT SERPINC1
20 aspirin allergy 10.4 SERPINC1 SERPINE1
21 sticky platelet syndrome 10.4 SERPINC1 SERPINE1
22 postaxial acrofacial dysostosis 10.4 PLAT THBD
23 scleroderma, familial progressive 10.3
24 subendocardial myocardial infarction 10.3 SERPINC1 SERPINE1
25 pleuropneumonia 10.3 PLAT SERPINC1
26 ligneous conjunctivitis 10.3 PLAT PLG
27 inferior myocardial infarction 10.3 PLAT PLG
28 eisenmenger syndrome 10.3 PLAT THBD
29 central retinal artery occlusion 10.3 PLAT PLG
30 alpha-2-plasmin inhibitor deficiency 10.3 PLG SERPINC1
31 occlusion precerebral artery 10.3 PLAT PLG
32 basilar artery occlusion 10.3 PLAT PLG
33 tuberculous empyema 10.3 PLG SERPINE1
34 heparin-induced thrombocytopenia 10.3 F3 SERPINC1
35 chronic venous insufficiency 10.3 PLAT SERPINE1
36 retinal vascular occlusion 10.3 PLG SERPINC1
37 anterior spinal artery syndrome 10.3 PLG SERPINC1
38 sagittal sinus thrombosis 10.3 F3 SERPINC1
39 leukemia, acute myeloid 10.3
40 myeloid leukemia 10.3
41 venous insufficiency 10.3 PLAT SERPINE1
42 angina pectoris 10.3 PLAT SERPINC1
43 catastrophic antiphospholipid syndrome 10.3 F3 SERPINE1
44 purpura fulminans 10.3 F3 SERPINC1
45 hepatic infarction 10.3 F3 SERPINC1
46 conjugate gaze palsy 10.2 F3 PLG
47 fibrinolytic defect 10.2 PLAT SERPINC1 SERPINE1
48 cerebral falx meningioma 10.2 F3 PLG
49 peripheral vertigo 10.2 F3 SERPINC1
50 argentine hemorrhagic fever 10.2 PLAT SERPINC1 SERPINE1

Comorbidity relations with Hepatic Veno-Occlusive Disease via Phenotypic Disease Network (PDN):


Heart Disease

Graphical network of the top 20 diseases related to Hepatic Veno-Occlusive Disease:



Diseases related to Hepatic Veno-Occlusive Disease

Symptoms & Phenotypes for Hepatic Veno-Occlusive Disease

Human phenotypes related to Hepatic Veno-Occlusive Disease:

60 33 (show all 13)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hepatomegaly 60 33 hallmark (90%) Very frequent (99-80%) HP:0002240
2 renal insufficiency 60 33 hallmark (90%) Very frequent (99-80%) HP:0000083
3 ascites 60 33 hallmark (90%) Very frequent (99-80%) HP:0001541
4 abdominal pain 60 33 hallmark (90%) Very frequent (99-80%) HP:0002027
5 jaundice 60 33 hallmark (90%) Very frequent (99-80%) HP:0000952
6 respiratory failure 60 33 hallmark (90%) Very frequent (99-80%) HP:0002878
7 increased body weight 60 33 hallmark (90%) Very frequent (99-80%) HP:0004324
8 increased total bilirubin 60 33 hallmark (90%) Very frequent (99-80%) HP:0003573
9 elevated hepatic transaminase 33 hallmark (90%) HP:0002910
10 prolonged partial thromboplastin time 60 33 frequent (33%) Frequent (79-30%) HP:0003645
11 hepatic encephalopathy 60 33 very rare (1%) Very rare (<4-1%) HP:0002480
12 elevated hepatic transaminases 60 Very frequent (99-80%)
13 abnormality of coagulation 60 Frequent (79-30%)

MGI Mouse Phenotypes related to Hepatic Veno-Occlusive Disease:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.97 F3 F8 FGF2 PLAT PLG SERPINC1
2 cardiovascular system MP:0005385 9.91 F3 FGF2 PLAT PLG SERPINC1 SERPINE1
3 homeostasis/metabolism MP:0005376 9.91 F3 F8 FGF2 PLAT PLG SERPINC1
4 immune system MP:0005387 9.76 F3 F8 PLAT PLG SERPINC1 SERPINE1
5 reproductive system MP:0005389 9.43 F8 FGF2 PLAT PLG SERPINC1 THBD
6 respiratory system MP:0005388 9.02 F3 PLAT PLG SERPINE1 THBD

Drugs & Therapeutics for Hepatic Veno-Occlusive Disease

Drugs for Hepatic Veno-Occlusive Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 122)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Busulfan Approved, Investigational Phase 4,Phase 2,Not Applicable 55-98-1 2478
2
Ledipasvir Approved Phase 4 1256388-51-8 67505836
3
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
4
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 75607-67-9, 21679-14-1 30751
5
Vidarabine Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 24356-66-9 21704 32326
6 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
7 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
8 Antimetabolites Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
9 Antimetabolites, Antineoplastic Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
10 Antineoplastic Agents, Alkylating Phase 4,Phase 2,Not Applicable
11 Alkylating Agents Phase 4,Phase 2,Not Applicable
12 Ledipasvir, sofosbuvir drug combination Phase 4
13 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15
Levoleucovorin Approved, Investigational Phase 2, Phase 3 68538-85-2
16
leucovorin Approved Phase 2, Phase 3,Phase 3,Phase 1 58-05-9 6006 143
17
Methotrexate Approved Phase 2, Phase 3,Phase 1 1959-05-2, 59-05-2 126941
18
Defibrotide Approved, Investigational Phase 3,Phase 2 83712-60-1
19
inotuzumab ozogamicin Approved, Investigational Phase 3,Phase 2 635715-01-4
20
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
21
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
22
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3,Phase 1 59-30-3 6037
23 Nucleic Acid Synthesis Inhibitors Phase 2, Phase 3,Phase 1
24 Micronutrients Phase 2, Phase 3
25 Vitamin B9 Phase 2, Phase 3,Phase 1
26 Folate Phase 2, Phase 3,Phase 1
27 Dermatologic Agents Phase 2, Phase 3,Phase 1,Not Applicable
28 Antirheumatic Agents Phase 2, Phase 3,Phase 1,Not Applicable
29 Folic Acid Antagonists Phase 2, Phase 3,Phase 1
30 Protective Agents Phase 2, Phase 3,Not Applicable
31 Vitamins Phase 2, Phase 3
32 Trace Elements Phase 2, Phase 3
33 Nutrients Phase 2, Phase 3
34 Vitamin B Complex Phase 2, Phase 3,Phase 1
35 Hematinics Phase 2, Phase 3
36 Antidotes Phase 2, Phase 3
37 Anticoagulants Phase 3,Phase 2
38 Anti-Inflammatory Agents Phase 3
39 Coagulants Phase 3
40 Fibrinolytic Agents Phase 3,Phase 2
41 Platelet Aggregation Inhibitors Phase 3,Phase 2
42 Liver Extracts Phase 3,Not Applicable
43 Peripheral Nervous System Agents Phase 3
44 Analgesics Phase 3
45 Topoisomerase Inhibitors Phase 3,Phase 2,Not Applicable
46
Mercaptopurine Approved Phase 1, Phase 2 50-44-2 667490
47
Thioguanine Approved Phase 1, Phase 2 154-42-7 2723601
48
carbamide peroxide Approved Phase 2 124-43-6
49
Mechlorethamine Approved, Investigational Phase 2,Not Applicable 51-75-2 4033
50
Etoposide Approved Phase 2,Not Applicable 33419-42-0 36462

Interventional clinical trials:

(show all 45)
# Name Status NCT ID Phase Drugs
1 Ultrasound Elastography to Predict Development of SOS Recruiting NCT03858530 Phase 4
2 Busulfan Pharmacokinetic Analysis and GST Polymorphism in Adults Undergoing Hematological Stem Cell Transplantation Withdrawn NCT01071486 Phase 4 Hematological Stem Cell Transplantation
3 Ledipasvir/Sofosbuvir Treatment for Hepatitis C in HCT Recipients. Withdrawn NCT03279133 Phase 4 Ledipasvir 90mg/Sofosubvir 400mg
4 Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT) Completed NCT00361140 Phase 4 Busulfan;Fludarabine
5 The Effect of Folinic Acid Rescue Following MTX GVHD Prophylaxis on Regimen Related Toxicity and Transplantation Outcome Unknown status NCT02506231 Phase 2, Phase 3 Folinic acid;Placebo
6 Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study Completed NCT00628498 Phase 3 Defibrotide;Defibrotide
7 Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients Completed NCT00358501 Phase 3 Defibrotide
8 Study Comparing Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Recruiting NCT02851407 Phase 3 Defibrotide
9 Pediatric Trial Investigating the Incidence & Outcome of Veno-Occlusive Disease With the Prophylactic Use of Defibrotide Completed NCT00272948 Phase 2, Phase 3 Defibrotide;Defibrotide;Defibrotide
10 A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia Completed NCT01564784 Phase 3 inotuzumab ozogamicin;FLAG (fludarabine, cytarabine and G-CSF);HIDAC (high dose cytarabine);cytarabine and mitoxantrone
11 HLA 10/10 Matched Unrelated Donor vs Haploidentical Allogenic Hematopoietic Stem Cell Transplantation Not yet recruiting NCT03655145 Phase 3
12 Antithrombin-III for Patients With Hepatic Veno-occlusive Diseases Following Hematopoietic Stem Cell Transplantation Unknown status NCT01886248 Phase 2 Freeze-dried Concentrated Human Antithrombin Ⅲ 500 IU
13 Thiopurine EnhAnced Maintenance Therapy Unknown status NCT02912676 Phase 1, Phase 2 Thioguanine (oral)
14 Chemotherapy Toxicity Reduction Via Urea Cycle Support Completed NCT00223730 Phase 2 Citrulline;Placebo
15 Defibrotide TMA Prophylaxis Pilot Trial Recruiting NCT03384693 Phase 2 Defibrotide
16 N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma Completed NCT00253435 Phase 2 Carboplatin;Etoposide;Melphalan
17 Busulfan/Clofarabine + Allogeneic Stem Cell Transplantation Completed NCT01643668 Phase 2 Busulfan;Clofarabine
18 Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients With Acute Graft Versus Host Disease (GVHD) Completed NCT01111526 Phase 1, Phase 2 Panobinostat (LBH589)
19 IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients Completed NCT01009840 Phase 2 IV busulfan;bortezomib
20 Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors Completed NCT00335556 Phase 2 Doxorubicin Hydrochloride;Irinotecan Hydrochloride;Cyclophosphamide;Etoposide;Carboplatin;Vincristine Sulfate
21 Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas Recruiting NCT02859402 Phase 2 Busulfan;Fludarabine
22 Total-Body Irradiation and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer and Other Diseases Completed NCT00317785 Phase 2 cyclophosphamide;cyclosporine;methotrexate;mycophenolate mofetil;sirolimus;tacrolimus
23 HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide Active, not recruiting NCT02793544 Phase 2 Fludarabine;Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5;Busulfan;Cyclophosphamide 50mg/kg/day IV on Days -2,-1;Cyclophosphamide 50mg/kg/day IV on Days -5,-4;Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4;Sirolimus;Mycophenolate mofetil;G-CSF;Pre-HCT Mesna on Days -6 and -5;Pre-HCT Mesna on Days -2 and -1;Pre-HCT Mesna on Days -5 and -4;Post-HCT Mesna
24 Bone Marrow Transplantation in Young Adults With Severe Sickle Cell Disease Completed NCT01565616 Phase 2 Conditioning Regimen with Bone Marrow Transplant
25 IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT Recruiting NCT03696537 Phase 1, Phase 2 Fludarabine
26 Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies Active, not recruiting NCT02333058 Phase 2 Treosulfan
27 Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia Recruiting NCT02981628 Phase 2
28 Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation Terminated NCT02338050 Phase 2
29 Conditioning SCID Infants Diagnosed Early Recruiting NCT03619551 Phase 2 Busulfan
30 Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia Recruiting NCT03739814 Phase 2
31 Haploidentical Hematopoietic Stem Cell Transplantation Recruiting NCT02165007 Phase 1 peripheral blood stem cell graft that are CD34+ selected
32 Effects on Glutamine on the Outcome of Allogeneic Bone Marrow Transplant Recipients Unknown status NCT00563498 Not Applicable Glutamine
33 Compassionate Use of Defibrotide for Patients With Veno-occlusive Disease of the Liver No longer available NCT00143546 Defibrotide
34 European VOD Registry Active, not recruiting NCT03032016
35 Prevention of the Hepatic Sinusoidal Obstruction Syndrome by Means of Anticoagulants Completed NCT00885950
36 Using Ultrasound Elastography to Predict Development of SOS Recruiting NCT02483481
37 Sinusoidal Obstruction Syndrome for Stem Cell Transplant Patients Biomarker Study Recruiting NCT03132337
38 Liver Stiffness Measurement Predicts VOD/SOS Development (ELASTOVOD ITALIAN MULTICENTRIC STUDY) Recruiting NCT03426358 Not Applicable
39 Jazz HCT Elastography Not yet recruiting NCT03865589 Not Applicable
40 Defibrotide Compassionate Use for Patients With Life Threatening Veno-Occlusive Disease of the Liver No longer available NCT00263978 Defibrotide
41 Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin Completed NCT01175356 Not Applicable cyclophosphamide;topotecan hydrochloride;cisplatin;etoposide phosphate;vincristine sulfate;doxorubicin hydrochloride;busulfan;melphalan;isotretinoin
42 Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Suspended NCT01798004 Not Applicable cyclophosphamide;topotecan hydrochloride;cisplatin;etoposide;vincristine sulfate;doxorubicin hydrochloride;busulfan;melphalan;mesna
43 Safety of Allogeneic Hematopoietic Cell Transplantation (HCT) For Patients With Classical Hodgkin Lymphoma (CHL) Treated With Nivolumab Recruiting NCT03200977
44 Study of Four Different Chemotherapy Regimens With or Without Total-Body Irradiation Followed by Umbilical Cord Blood Transplant in Treating Patients With Relapsed or Refractory Hematologic Cancer Active, not recruiting NCT00547196 Not Applicable busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;melphalan;mycophenolate mofetil
45 MRD Testing Before and After Hematopoietic Cell Transplantation for Pediatric Acute Myeloid Leukemia Completed NCT01385787

Search NIH Clinical Center for Hepatic Veno-Occlusive Disease

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: hepatic veno-occlusive disease

Genetic Tests for Hepatic Veno-Occlusive Disease

Anatomical Context for Hepatic Veno-Occlusive Disease

MalaCards organs/tissues related to Hepatic Veno-Occlusive Disease:

42
Liver, Bone, Bone Marrow, Endothelial, Myeloid, Kidney, Testes

Publications for Hepatic Veno-Occlusive Disease

Articles related to Hepatic Veno-Occlusive Disease:

(show top 50) (show all 443)
# Title Authors Year
1
"Liver Stiffness Measurement allows to early diagnose VOD/SOS in adult patients who underwent Hemopoietic Stem Cell Transplantation: results from a monocentric prospective study". ( 30660772 )
2019
2
The incidence and risk factors of hepatic veno-occlusive disease after hematopoietic stem cell transplantation in Taiwan. ( 30666432 )
2019
3
A Retrospective Analysis of Antithrombin III Replacement Therapy for the Treatment of Hepatic Sinusoidal Obstruction Syndrome in Children Following Hematopoietic Stem Cell Transplantation. ( 30676436 )
2019
4
Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease after Autologous or Allogeneic Hematopoietic Stem Cell Transplantation in Children: a retrospective study of the Italian Hematology-Oncology Association-Hematopoietic Stem Cell Transplantation Group. ( 30266674 )
2019
5
Ultrasound elastography techniques for diagnosis and follow-up of hepatic veno-occlusive disease. ( 30679827 )
2019
6
Risk Factors for Development of and Progression of Hepatic Veno-occlusive Disease/Sinusoidal Obstruction Syndrome. ( 30797942 )
2019
7
Hepatic sinusoidal obstruction syndrome following haematopoietic stem cell transplantation. A report of 33 cases. ( 29887172 )
2019
8
Treprostinil reduces endothelial damage in murine sinusoidal obstruction syndrome. ( 30535954 )
2019
9
Indirect costs associated with premature mortality among those with veno-occlusive disease/sinusoidal obstruction syndrome with multiorgan dysfunction post-hematopoietic stem-cell-transplant. ( 30588050 )
2019
10
Expert consensus on the clinical management of pyrrolizidine alkaloid induced hepatic sinusoidal obstruction syndrome. ( 30669184 )
2019
11
Assessment of the proposed EBMT pediatric criteria for diagnosis and severity grading of sinusoidal obstruction syndrome. ( 30683907 )
2019
12
Gadoxetic Acid-Enhanced Hepatobiliary-Phase Magnetic Resonance Imaging for Pyrrolizidine Alkaloid-Induced Hepatic Sinusoidal Obstruction Syndrome and Association with Liver Function. ( 30718698 )
2019
13
Quantitative Analysis of CT Images in Patients with Pyrrolizidine Alkaloid-Induced Sinusoidal Obstruction Syndrome. ( 30778132 )
2019
14
Systematic review of defibrotide studies in the treatment of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS). ( 30804485 )
2019
15
Validation of treatment outcomes according to revised severity criteria from European Society for Blood and Marrow Transplantation (EBMT) for sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD). ( 30809031 )
2019
16
(-)-Epicatechin attenuates hepatic sinusoidal obstruction syndrome by inhibiting liver oxidative and inflammatory injury. ( 30822691 )
2019
17
Peripheral hepatic sinusoidal obstruction syndrome due to oxaliplatin-based chemotherapy. ( 30847217 )
2019
18
Defibrotide sodium for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome. ( 29301447 )
2018
19
Hepatic veno-occlusive disease following sirolimus-based immune suppression. ( 29895929 )
2018
20
Evaluation of Therapeutic Effect of Rice Husk Silica Combined with Platelets Derived Growth Factor in Hepatic Veno- Occlusive Disease. ( 29301090 )
2018
21
Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome. ( 29767845 )
2018
22
Hepatic veno-occlusive disease during isavuconazole administration. ( 29278102 )
2018
23
Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome following nontransplant-associated chemotherapy: Final results from a post hoc analysis of data from an expanded-access program. ( 29873895 )
2018
24
Late-Onset Hepatic Veno-Occlusive Disease after Allografting: Report of Two Cases with Atypical Clinical Features Successfully Treated with Defibrotide. ( 29326798 )
2018
25
Hepatobiliary and Pancreatic: Pregnancy induced hepatic veno-occlusive disease requiring liver transplantation. ( 29284078 )
2018
26
Hepatic veno-occlusive disease related to Gynura segetum: A case report. ( 29703039 )
2018
27
Gallbladder wall oedema and ascites are independent predictors of progression to hepatic veno-occlusive disease for children with hematopoietic stem cell transplantation. ( 29294155 )
2018
28
Novel Ultrasonographic Scoring System of Sinusoidal Obstruction Syndrome after Hematopoietic Stem Cell Transplantation. ( 29803752 )
2018
29
Clinical effects of recombinant thrombomodulin and defibrotide on sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation. ( 30127466 )
2018
30
Identification and Management: Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease Eelated to Hematopoietic Stem Cell Transplantation
. ( 29350698 )
2018
31
Association of CTH variant with sinusoidal obstruction syndrome in children receiving intravenous busulfan and cyclophosphamide before hematopoietic stem cell transplantation. ( 27779248 )
2018
32
Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation. ( 30081073 )
2018
33
Treatment of hepatic veno-occlusive disease in children with N-acetylcysteine. ( 30350914 )
2018
34
Risk factors for hepatic veno-occlusive disease caused by Gynura segetum: a retrospective study. ( 30367628 )
2018
35
Fulminant hepatitis due to very severe sinusoidal obstruction syndrome (SOS/VOD) after autologous peripheral stem cell transplantation: a case report. ( 29970140 )
2018
36
Prophylactic recombinant thrombomodulin treatment prevents hepatic sinusoidal obstruction syndrome in high-risk pediatric patients that undergo hematopoietic stem cell transplants. ( 30003636 )
2018
37
Direct Intrahepatic Portocaval Shunt for Sinusoidal Obstruction Syndrome Associated with Hepatotoxicity of Pyrrolizidine Alkaloids. ( 30009181 )
2018
38
Comprehensive analysis of serum microRNAs in hepatic sinusoidal obstruction syndrome (SOS) in rats: implication as early phase biomarkers for SOS. ( 30019166 )
2018
39
New Ultrasound Techniques Challenge the Diagnosis of Sinusoidal Obstruction Syndrome. ( 30076031 )
2018
40
Soluble Thrombomodulin Attenuates Endothelial Cell Damage in Hepatic Sinusoidal Obstruction Syndrome. ( 30348695 )
2018
41
Gynura Rhizoma containing pyrrolizidine alkaloids induces the hepatic sinusoidal obstruction syndrome in mice via upregulating fibrosis-related factors. ( 30367152 )
2018
42
Role of Virtual Touch Tissue Imaging Quantification in the Assessment of Hepatic Sinusoidal Obstruction Syndrome in a Rat Model. ( 30561767 )
2018
43
Sinusoidal Obstruction Syndrome (SOS) in Multiple Myeloma with Renal Failure. ( 30631618 )
2018
44
Sinusoidal obstruction syndrome in a paediatric patient with acute lymphoblastic leukaemia after completion of reinduction therapy according to ALL Intercontinental Berlin-Frankfurt-Münster 2009. ( 30783392 )
2018
45
Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation. ( 28759025 )
2018
46
Defibrotide: An Oligonucleotide for Sinusoidal Obstruction Syndrome. ( 28914546 )
2018
47
Phosphodiesterase III inhibitor attenuates rat sinusoidal obstruction syndrome through inhibition of platelet aggregation in Disse's space. ( 28960464 )
2018
48
Defibrotide for the treatment of sinusoidal obstruction syndrome: evaluation of response to therapy and patient outcomes. ( 29022099 )
2018
49
Abdominal computed tomography angiography in post-transplantation sinusoidal obstruction syndrome associated with R-DHAOX/BEAM toxicity. ( 29181839 )
2018
50
Using liver elastography to diagnose sinusoidal obstruction syndrome in pediatric patients undergoing hematopoetic stem cell transplant. ( 29335626 )
2018

Variations for Hepatic Veno-Occlusive Disease

Expression for Hepatic Veno-Occlusive Disease

Search GEO for disease gene expression data for Hepatic Veno-Occlusive Disease.

Pathways for Hepatic Veno-Occlusive Disease

Pathways related to Hepatic Veno-Occlusive Disease according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.84 F3 F8 PLAT PLG SERPINC1 SERPINE1
2
Show member pathways
12.5 F3 F8 SERPINC1 THBD
3
Show member pathways
12.03 PLAT PLG SERPINE1
4 11.7 F3 PLG SERPINE1
5
Show member pathways
11.7 F3 F8 PLAT PLG SERPINC1 SERPINE1
6 11.58 F3 SERPINE1 THBD
7 11.33 PLAT PLG SERPINE1
8 11.31 F3 F8 PLAT PLG SERPINC1 SERPINE1
9 11.19 FGF2 PLAT PLG
10 11 FGF2 PLG
11 10.91 FGF2 SERPINC1
12 10.82 PLAT PLG
13 10.55 PLAT PLG SERPINE1

GO Terms for Hepatic Veno-Occlusive Disease

Cellular components related to Hepatic Veno-Occlusive Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.76 F3 F8 FGF2 PLAT PLG SERPINC1
2 cell surface GO:0009986 9.62 F3 PLAT PLG THBD
3 platelet alpha granule lumen GO:0031093 9.43 F8 PLG SERPINE1
4 collagen-containing extracellular matrix GO:0062023 9.35 F3 PLAT PLG SERPINC1 SERPINE1
5 extracellular space GO:0005615 9.28 F3 F8 FGF2 PLAT PLG SERPINC1

Biological processes related to Hepatic Veno-Occlusive Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of protein kinase B signaling GO:0051897 9.63 F3 FGF2 THPO
2 positive regulation of angiogenesis GO:0045766 9.61 F3 FGF2 SERPINE1
3 platelet degranulation GO:0002576 9.54 F8 PLG SERPINE1
4 fibrinolysis GO:0042730 9.43 PLAT PLG SERPINE1
5 blood coagulation GO:0007596 9.43 F3 F8 PLAT PLG SERPINC1 THBD
6 negative regulation of blood coagulation GO:0030195 9.4 SERPINE1 THBD
7 negative regulation of fibrinolysis GO:0051918 9.33 PLG SERPINE1 THBD
8 negative regulation of wound healing GO:0061045 9.32 FGF2 SERPINE1
9 hemostasis GO:0007599 9.02 F3 F8 PLG SERPINC1 THBD

Molecular functions related to Hepatic Veno-Occlusive Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 serine-type endopeptidase activity GO:0004252 9.33 F3 PLAT PLG
2 signaling receptor binding GO:0005102 9.26 PLAT PLG SERPINE1 THPO
3 protease binding GO:0002020 8.8 F3 SERPINC1 SERPINE1

Sources for Hepatic Veno-Occlusive Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....